Recent Updates

Devon Formulary and Referral User Survey 2017

We would like to invite you to take part in the Devon formulary and referral user survey. This should take no more than about 10 minutes of your time.

The survey can be accessed by clicking on the following link:

https://www.surveymonkey.co.uk/r/MG78882

The survey is being conducted to enable the team to understand and improve user experience and satisfaction. Your feedback is essential to inform the future direction of the formulary.

Feedback and suggestions via the survey are welcomed, particularly around the relevance, complexity and quantity of content; site navigation and searching; and the "traffic light" drug classification system.

We would like to thank you in advance for your participation and to assure confidentiality of all responses.

The deadline for responses is Monday 18th December 2017

November 2017

Soltel® aerosol inhalation 25micrograms/ metered inhalation (£19.95 = 120 doses) has been added into the formulary as the preferred brand of salmeterol inhaler. Soltel is contraindicated in patients who have peanut and soya allergies. Please see the formulary for further information.

Rivaroxaban 2.5mg tablets (£50.40 = 56 tablets) has been reclassified as amber specialist use; it is included for use in patients who have had an acute coronary syndrome with elevated cardiac biomarkers, in line with NICE TA335. Please see the formulary for further information.

Formulary choice oral nutritional supplements: Following consultation with local dietitian specialists in South and West Devon, the choices of formulary oral nutritional supplements have been reviewed. The choices provided have been chosen based on palatability, range of flavours, and cost efficiency. Please see the formulary for further guidance.

Further specialist oral nutritional supplements are available, that are not included in the formulary, but are suitable to be prescribed at a specialist dietitian's request.

September 2017

Spiolto® Respimat®(combination of tiotropium and olodaterol) 2.5micrograms/ 2.5micrograms solution for inhalation has been added into the formulary for the management of chronic obstructive pulmonary disease (COPD), following a commissioning decision form the Clinical Policy Committee. Please see the formulary for further information. It should be noted that the MHRA Drug Safety Update (February 2015) applies to Spiolto® Respimat® as tiotropium is delivered via Respimat® or HandiHaler®.

Monuril® sachets 3g have been added into the formulary as the preferred brand of fosfomycin, for the treatment of uncomplicated urinary tract infection (UTI) in adults if first line options are unsuitable. Please see the formulary for further information.

Levetiracetam granules sugar free sachets 250mg, 500mg, and 1g, have been added into the formulary for use in paediatric patients who cannot take the tablets, and cannot tolerate the oral solution. Please see the formulary for further information.

Enoxaparin sodium prefilled syringes for injection have been updated with the latest strength expressions, after a letter was sent to healthcare professionals to highlight an inclusion of international units (IU) of anti-Xa activity. One mg of enoxaparin sodium is equivalent to 100 IU anti-Xa activity. Please see the formulary for further information.

Alzain® has been removed from the formulary as the preferred brand of pregabalin. Generic prescribing is now recommended. Please see the formulary for further information. Please see the formulary for further information.

Antimicrobials and infections: The infections chapter of the formulary has been updated in line with Public Health England: Management of infection guidance for primary care for consultation and local adaptation (May 2017), and local microbiologist specialists. Please see the formulary for up to date guidance. Pivmecillinam tablets 200mg and Fosfomycin (Monuril®) sachets 3g have been reclassified as blue second line treatment of uncomplicated UTI in adults if first line options are unsuitable, following advice and recommendation from local microbiologist specialists. Please see the formulary for further information.

Compression hosiery and garments: Following consultation with local tissue viability specialist nurses, this guidance has been reviewed and refreshed to provide unified care across settings, to encourage patient concordance by offering a vast choice of hosiery suitable for patient needs and lower limb conditions. Please see the formulary for up to date guidance.

Management of low back pain and sciatica: This has been added into the formulary. Please refer to the formulary for this guidance

July 2017

Fiasp® insulin aspart 100 units per 1ml, 10ml vials, 3ml cartridges, and 3ml FlexTouch® prefilled devices have been added into the formulary for use in patients aged 18 years and over. Please see the formulary for further information.

Lecicarbon A suppositories have been added into the formulary for the management of chronic constipation, following a commissioning decision from the Clinical Policy Committee. Please see the formulary for further information.

Ralvo® medicated plasters 700mg (5% w/w) have been added as a preferred brand of lidocaine plasters, for the treatment of post-herpetic neuralgia, and should only be used following initiation by the Pain Clinic. Please see the formulary for further information.

Sodium oxybate oral solution 500mg in 1ml has been added into the formulary for the management of narcolepsy with cataplexy in adults aged 19 years and older, in line with specific criteria, following a commissioning decision from the Clinical Policy Committee. Please see the formulary for further information.

Emergency contraception: The guidance for emergency contraception has been reviewed and updated, following new advice from The Faculty of Sexual and Reproductive Healthcare (FSRH) Please see the formulary for up to date guidance. Ulipristal acetate tablets 30mg has been reclassified as green first line preferred treatment of emergency contraception, and Levonorgestrel tablets 1.5mg has been reclassified as blue second line treatment, following the update. Please see the formulary for further information.

Management of epilepsy: The guidance has been refreshed and expanded to emphasise MHRA Drug Safety Updates. Please see the formulary for up to date guidance and further information.

 

Home > Formulary > Updates > Recent Updates

 

  • First line
  • Second line
  • Specialist
  • Hospital